key: cord-0956402-0i784x08
authors: Artese, Anna; Svicher, Valentina; Costa, Giosuè; Salpini, Romina; Di Maio, Velia Chiara; Alkhatib, Mohammad; Ambrosio, Francesca Alessandra; Santoro, Maria Mercedes; Assaraf, Yehuda G.; Alcaro, Stefano; Ceccherini-Silberstein, Francesca
title: Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
date: 2020-08-26
journal: Drug Resist Updat
DOI: 10.1016/j.drup.2020.100721
sha: bebdda66983a8fae892d8b80292717aabf0eb754
doc_id: 956402
cord_uid: 0i784x08

Coronaviridae is a peculiar viral family, with a very large RNA genome and characteristic appearance, endowed with remarkable tendency to transfer from animals to humans. Since the beginning of the 21st century, three highly transmissible and pathogenic coronaviruses have crossed the species barrier and caused deadly pneumonia, inflicting severe outbreaks and causing human health emergencies of inconceivable magnitude. Indeed, in the past two decades, two human coronaviruses emerged causing serious respiratory illness: severe acute respiratory syndrome coronavirus (SARS-CoV-1) and Middle Eastern respiratory syndrome coronavirus (MERS-CoV), causing more than 10,000 cumulative cases, with mortality rates of 10 % for SARS-CoV-1 and 34.4 % for MERS-CoV. More recently, the severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) has emerged in China and has been identified as the etiological agent of the recent COVID-19 pandemic outbreak. It has rapidly spread throughout the world, causing nearly 22 million cases and ∼ 770,000 deaths worldwide, with an estimated mortality rate of ∼3.6 %, hence posing serious challenges for adequate and effective prevention and treatment. Currently, with the exception of the nucleotide analogue prodrug remdesivir, and despite several efforts, there is no known specific, proven, pharmacological treatment capable of efficiently and rapidly inducing viral containment and clearance of SARS-CoV-2 infection as well as no broad-spectrum drug for other human pathogenic coronaviruses. Another confounding factor is the paucity of molecular information regarding the tendency of coronaviruses to acquire drug resistance, a gap that should be filled in order to optimize the efficacy of antiviral drugs. In this light, the present review provides a systematic update on the current knowledge of the marked global efforts towards the development of antiviral strategies aimed at coping with the infection sustained by SARS-CoV-2 and other human pathogenic coronaviruses, displaying drug resistance profiles. The attention has been focused on antiviral drugs mainly targeting viral protease, RNA polymerase and spike glycoprotein, that have been tested in vitro and/or in clinical trials as well as on promising compounds proven to be active against coronaviruses by an in silico drug repurposing approach. In this respect, novel insights on compounds, identified by structure-based virtual screening on the DrugBank database endowed by multi-targeting profile, are also reported. We specifically identified 14 promising compounds characterized by a good in silico binding affinity towards, at least, two of the four studied targets (viral and host proteins). Among which, ceftolozane and NADH showed the best multi-targeting profile, thus potentially reducing the emergence of resistant virus strains. We also focused on potentially novel pharmacological targets for the development of compounds with anti-pan coronavirus activity. Through the analysis of a large set of viral genomic sequences, the current review provides a comprehensive and specific map of conserved regions across human coronavirus proteins which are essential for virus replication and thus with no or very limited tendency to mutate. Hence, these represent key druggable targets for novel compounds against this virus family. In this respect, the identification of highly effective and innovative pharmacological strategies is of paramount importance for the treatment and/or prophylaxis of the current pandemic but potentially also for future and unavoidable outbreaks of human pathogenic coronaviruses.

Based on the mentioned considerations, some protease inhibitors and nucleoside analogues have been considered antiviral agents against SARS-CoV-2 (Table 1) .

Several clinical trials are ongoing to test whether protease inhibitors such as lopinavir, ritonavir and darunavir used for HIV treatment, or danoprevir used for HCV treatment, are also effective against SARS-CoV-2 (Table 1) (Lythgoe and Middleton, 2020 ; https://clinicaltrials.gov/; accessed on 12

August, 2020).

The combination of lopinavir/ritonavir is the most common exploratory antiviral regimen against SARS-CoV-2, appearing in 81 investigational studies (https://clinicaltrials.gov/; accessed on 12 August, 2020). Lopinavir is a potent antiretroviral protease inhibitor used in combination with ritonavir to treat patients with HIV infection (Croxtall and Perry, 2010) . Although ritonavir was initially developed as an HIV protease inhibitor, it is now almost exclusively used at a low dose as a pharmacokinetic booster to increase levels of other HIV protease inhibitors, including lopinavir, through inhibition of the Cytochrome P450 3A4 pathway (Hull and Montaner, 2011) . In vitro studies showed activity of lopinavir/ritonavir against the 3CL-PR of SARS-CoV-1 (Wu et al., 2004) . During the first SARS epidemic, the administration of lopinavir/ritonavir in combination with ribavirin in SARS-CoV-1-infected individuals, was associated with decreased viral load, decreased adverse clinical outcomes, acute respiratory distress syndrome, or death, when compared with historical control cases . The in vitro activity of lopinavir/ritonavir was also demonstrated against MERS-CoV (de Wilde et al., 2014) . In the marmoset model of MERS-CoV infection, the oral administration of lopinavir/ritonavir resulted in a modest improvement of MERS disease symptoms including decreased pulmonary infiltrates, decreased interstitial pneumonia, and decreased weight loss (J. F.-W. Chan et al., 2015) . In MERS-CoV-infected patients treated with regimens containing lopinavir/ritonavir, positive disease outcomes including defervescence, viral clearance from serum and sputum, and survival, were observed Bin et al., 2016) . Lopinavir/ritonavir has been also proposed as a possible treatment against SARS-CoV-2. However, the results of a trial performed on 199 hospitalized adult patients with confirmed SARS-CoV-2 infection in China showed that the use of lopinavir/ritonavir had no significant benefit beyond standard-care in either reduction of viral load or overall mortality . The authors reported several limitations, including lack of treatment blinding, with study participants and investigators being aware of treatment assignments, thus reducing study objectivity. Additional studies are certainly required to determine whether or not lopinavir/ritonavir treatment given at a certain stage of illness can reduce some COVID-19 complications. While already multiple other ongoing studies exploring lopinavir/ritonavir J o u r n a l P r e -p r o o f in SARS-CoV-2 infection are ongoing, none utilizes a double-blind methodology to address the mentioned above limitation.

Currently, the "COVID-19 Treatment Guidelines Panel" recommended the use of lopinavir/ritonavir or other protease inhibitors for the treatment of SARS-CoV-2 infections only in the context of clinical trials, because of unfavorable pharmacodynamics and negative clinical trial data (NIH, 2020) .

Concerning nucleoside analogues, those in the form of adenine or guanine analogues, target the RdRp and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses (Li and De Clercq, 2020) . This is the reason why several nucleos(t)ide analogues such as remdesivir, ribavirin and favipiravir have been considered potential drugs against SARS-CoV-2.

Remdesivir (GS-5734) was initially developed for the management of the Ebola and Marburg viruses (Warren et al., 2016; . This molecule is a small nucleotide analogue with a similar chemical structure of tenofovir alafenamide, a reverse transcriptase inhibitor approved for the treatment of HIV infection. Remdesivir has a broad antiviral activity in vitro against several RNA virus families including Filoviridae, Pneumoviridae, Paramyxoviridae, and Coronaviridae (Warren et al., 2016; Lo et al., 2017; Sheahan et al., 2017; Totura and Bavari, 2019) . Several in vitro and in vivo data on remdesivir against a panel of coronaviruses, including highly pathogenic coronaviruses and potentially emergent BatCoVs (BatCoV-HKU5, BatCoV-HKU3, BatCoV-SHC014, and BatCoV-WIV1), support the development of this drug as an important potential pancoronavirus antiviral agent Agostini et al., 2018; Totura and Bavari, 2019) . In particular, studies demonstrated that remdesivir decreases viral titers and viral RNA in in vitro models of both SARS-CoV-1 and MERS-CoV infection of primary human airway epithelial (HAE) cell cultures Totura and Bavari, 2019) , and a recent study reported that this molecule inhibits SARS-CoV-2 (EC50 = 0.77 μM in Vero E6 cells) (M. . Moreover, in vivo activity against coronaviruses was supported by improved disease signs (weight loss, lung viral titers) in MA15 SARS-CoV-infected mice treated prophylactically or therapeutically with remdesivir Totura and Bavari, 2019) . There has been much interest in remdesivir, following treatment of the first SARS-CoV-2 case, and subsequent recovery (Holshue et al., 2020) . Currently, 44 trials taking place globally to investigate the efficacy of remdesivir for SARS-CoV-2 infection have been registered (https://clinicaltrials.gov/; accessed on 12 August, 2020).

Potentially important clinical benefit of using remdesivir for COVID-19 patients emerged from an expanded access program (Grein et al., 2020) . More recently however, data published from a first randomized clinical trial from China in adults with severe SARS-CoV-2 infection, did not show an association of remdesivir with statistically significant clinical benefits (Y. . Of note, the study was prematurely terminated due to low patient enrolment, which would limit its power.

In the Adaptive COVID-19 Treatment Trial (ACTT), including 1063 adult hospitalized patients with SARS-CoV-2 infection and evidence of lower respiratory tract involvement, a lower median time of recovery was found in patients treated with remdesivir compared to those who received placebo (11 [95% C.I: 9-12] versus 15 [95% C.I: 13-19] days, p<0.001) (Beigel et al., 2020) . Moreover, results from the SIMPLE trial showed that in patients with severe SARS-CoV-2 infection not requiring mechanical ventilation, a five-day dosing duration of remdesivir led to "similar improvement in clinical status" as the 10-day treatment course (Goldman et al., 2020) . This study was not placebocontrolled; therefore the magnitude of benefit could not be determined. Recently, an expansion phase of the study has been added and will enroll a large cohort of 5600 additional patients, including those on mechanical ventilation.

On the basis of preliminary clinical trial data, the American COVID-19 Treatment Guidelines Panel recommended the administration of the investigational antiviral agent remdesivir to hospitalized patients infected with SARS-CoV-2 displaying a severe disease (NIH, 2020). However, remdesivir is not approved by the Food and Drug Administration (FDA). It is available only through an FDA emergency use authorization, in clinical trials, or through an emergency access program for children and adult patients hospitalized with severe COVID-19 (Updated 7/30/2020). On 25 June 2020, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the granting of a conditional marketing authorization for remdesivir. It is currently indicated for the treatment of COVID-19 in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen (European Medicines Agency, 2020b).

Ribavirin is a guanosine analogue previously approved and largely used for the treatment of HCV and respiratory syncytial virus (RSV). This drug shows in vitro activity against a large number of highly lethal emerging viruses. Ribavirin inhibits RNA synthesis by interfering with viral RdRp as well as inhibiting mRNA capping. However, while studies in vitro demonstrated that SARS-CoV-1, MERS-CoV, and HCoV-OC43 were sensitive to ribavirin, the doses that significantly inhibited the viral replication exceeded ribavirin blood concentrations attainable by typical human regimens (Totura and Bavari, 2019). Coronaviruses are one of few RNA viruses with a genomic proofreading mechanism, and therefore, a decreased in vitro activity of ribarivin than expected, was observed. This J o u r n a l P r e -p r o o f decrease is related to the excision of ribavirin and other nucleoside analogues by conserved coronavirus proofreading mechanisms (Ferron et al., 2018) . Moreover, a limited activity against MA15 SARS-CoV by ribavirin alone was found in mouse models, thus suggesting that ribavirin treatment exacerbated SARS disease symptoms (Day et al., 2009) . However, combination treatment of ribavirin and type I Interferons in primate models, improved MERS disease signs (Falzarano, De Wit, Rasmussen, et al., 2013) . Ribavirin was used as part of treatment regimens for SARS and MERS patients; but, its efficacy was very limited in patients with highly pathogenic coronavirus respiratory syndromes (Totura and Bavari, 2019). Whether ribavirin exerts sufficient potency against SARS-CoV-2 remains to be determined.

Favipiravir (T-705), a guanine analogue approved for influenza treatment, can effectively inhibit the RdRp of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus (Oestereich et al., 2014; Li and De Clercq, 2020) . This compound showed in vitro activity against SARS-CoV-2 as well, albeit at a high concentration (EC50 = 61.88 μM in Vero E6 cells) (M. . Further in vivo studies are required to evaluate this antiviral nucleoside analogue.

Patients with SARS-CoV-2 are being recruited in randomized trials to evaluate the efficacy of favipiravir in combination with interferon-α and favipiravir in combination with baloxavir marboxil (an approved influenza inhibitor targeting the cap-dependent endonuclease).

Further potential drug candidates for the treatment of SARS-CoV-2 infections are chloroquine phosphate and hydroxychloroquine sulfate. Chloroquine is an aminoquinolone derivative. Since its development in the 1940s, it was the drug of choice in the treatment of malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine (Plantone and Koudriavtseva, 2018) . Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other conditions including HIV, drug-resistant HCVinfection, systemic lupus erythematosus, and rheumatoid arthritis (Plantone and Koudriavtseva, 2018) . These two drugs are being investigated for the treatment of SARS-CoV-2 (Devaux et al., 2020; Yao et al., 2020) . They inhibit terminal glycosylation of ACE2, the receptor that both SARS-CoVs target for cell entry. ACE2 not fully glycosylated may less efficiently interact with the SARS-CoV spike glycoproteins, thus facilitating the inhibition of viral entry (Vincent et al., 2005) . In vitro, they inhibit several human pathogenic coronaviruses (Vincent et al., 2005; Devaux et al., 2020; Yao et al., 2020) . In particular, both chloroquine and hydroxychloroquine potently inhibit SARS-CoV-2 with a low micromolar concentration (Table 1) .

Several clinical trials are undergoing to investigate the efficacy of these two drugs against SARS-CoV-2 (https://clinicaltrials.gov/; accessed on 12 August 2020). Several critical scientific questions have been raised about data reported in the paper by Mandeep Mehra et al., -Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis1-published in The Lancet on May 22, 2020, that was later retracted (The Lancet Editors, 2020). A recent randomized, placebo-controlled trial on 821 asymptomatic participants found hydroxychloroquine was no better than a placebo in preventing infection of the coronavirus (Boulware et al., 2020) . At the same time, a targeted update on the 11 th of June 2020 of the systematic review and meta-analyses about the efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19, highlighted that so far there is very low certainty evidence from randomized clinical trials and quasi-experimental studies that hydroxychloroquine results in little or no benefit over standard care for the treatment of COVID-19 (WHO. COVID-NMA project.

Cochrane, 2020). Overall, potential prevention and/or clinical benefits of hydroxychloroquine use remain to be determined.

Another drug that can interfere with viral entry, by targeting the viral spike glycoprotein, is griffithsin. This drug is a red-alga-derived lectin that binds to oligosaccharides on the surface of various viral glycoproteins, including HIV glycoprotein 120, and SARS-CoV spike glycoprotein (Lusvarghi and Bewley, 2016; Li and De Clercq, 2020 ). Griffithsin has been tested in phase I studies for HIV prevention, but studies are required to investigate the potency and delivery systems of spike inhibitors for the treatment or prevention of SARS-CoV-2.

It has been demonstrated that the binding of the coronavirus spike protein to ACE2 leads to ACE2 downregulation, thus resulting in excessive production of angiotensin. This in turn contributes to lung injury, as angiotensin-stimulated a type I angiotensin II receptor (AT1R) resulting in increased pulmonary vascular permeability, thereby mediating increased lung pathology (Imai et al., 2005) . Therefore, although it could seem paradoxical, higher ACE2 expression due to the treatment of SARS-CoV-2 infected patients with AT1R blockers may protect them against acute lung injury rather than exposing them at higher risk to develop SARS-CoV infection.

Recently, Shuai Xia and colleagues found that the lipopeptide EK1C4 acts as a potent fusion inhibitor against SARS-CoV-2 spike protein-mediated membrane fusion and pseudovirus infection with IC50 values of 1.3 and 15.8 nM, respectively (Xia, Liu, et al., 2020) . This lipopeptide is about 241-and 149-fold more potent than the original pan-coronavirus fusion inhibitor, EK1, which targeted the HR1 domain (Xia et al., 2019) . A high activity of EK1C4 was also shown against membrane fusion and infection of other human coronavirus pseudoviruses, including SARS-CoV-1 and MERS-CoV; moreover, EK1C4 potently inhibited the replication of five live human J o u r n a l P r e -p r o o f coronaviruses, including SARS-CoV-2 (Xia, Liu, et al., 2020) . In mice, a protection against HCoV-OC43 infection was found by using intranasal application of EK1C4 before or after challenge with HCoV-OC43, suggesting that EK1C4 could be used for prevention and treatment of infection by the currently circulating SARS-CoV-2 and other emerging SARS-CoVs (Xia, Liu, et al., 2020) .

Drug resistance development is influenced by several parameters including drug potency and genetic barrier, host factors as well as viral factors such as viral fitness and intrinsic biology.

Considering viral factors, RNA viruses are generally characterized by a higher degree of genetic variability (Lauring and Andino, 2010) . This is due to lack of proofreading activity by RdRp leading to high error rates and low replicative fidelity. Coronaviruses represent an exception to this rule, since they are the only RNA viruses encoding an exoribonuclease activity in the nonstructural protein 14 (ExoN) (Denison et al., 2011; Pruijssers and Denison, 2019) . The presence of ExoN represents an obstacle to the development of nucleos(t)ide analogues, a broad-spectrum class of viral RdRp inhibitors largely used in treating multiple viral infections . Indeed, ExoN acts by removing incorporated nucleos(t)ide analogues, conferring a sort of "innate" resistance to the majority of these compounds (Pruijssers and Denison, 2019; Shannon et al., 2020) and introducing a unique concept in mechanisms modulating drug resistance emergence. In line with this concept, in vitro studies showed that murine hepatitis virus (MHV) and SARS-CoV strains, lacking the proofreading activity of ExoN, were more susceptible to 5-fluorouracil and ribavirin than wild type (Smith et al., 2013) . Similarly, a previous study has shown that the RdRp mutations V553I and M611F capable to affect the fidelity of RdRp can confer resistance to 5-fluorouracil and/or to 5azacytidine only when the activity of ExoN was abrogated, supporting that ExoN proofreading activity exerts an epistatic effect to the nucleotide selectivity of RdRp (Table 2) (Sexton et al., 2016) .

Overall, this supports a cooperation between RdRp and ExoN to optimize both fidelity and replication kinetics (Sexton et al., 2016) .

So far, only two nucleos(t)ide analogues potently inhibit the coronavirus replication even in presence of ExoN. This is the case of remdesivir and the ribonucleoside analogue β-D-N4hydroxycytidine, for whom an additional mechanism of action (beyond acting as chain terminator) has been hypothesized (Agostini et al., , 2019 . Both compounds are characterized by a high barrier towards resistance-acquisition in in vitro studies. For remdesivir, drug resistance was observed after several passages in MHV at residues F476L and V553L (Table 2 ). These mutations correspond to F480L and V557L in SARS-CoV-1 RdRp and can confer resistance also in SARS-CoV-1 despite affecting viral fitness and virulence (Table 2) . Regarding β-D-N4-J o u r n a l P r e -p r o o f hydroxycytidine, a low level resistance was detected only after the appearance of several mutations in MHV and MERS-CoV (Agostini et al., 2019) .

Few resistance data were reported on 3CL-PR inhibitors. Using MHV in vitro model, single mutation (T26I and D65G) and double mutations (T26I+D65G and T26I+A298D) ( Table 2) were associated with drug resistance to the broad-spectrum 3CL-PR inhibitor GRL-001 (Deng et al., 2014) .

Drug resistance mutations emerged after only four passages in cell culture suggesting a low barrier to resistance of this compound. Again, the emergence of drug resistance was associated with a reduced viral replication capacity and virulence supporting a high cost in term of viral fitness (Deng et al., 2014) .

Recent reports described the effects of specific 3CL-PR mutations (N25S, A252S and K260N) emerging in a patient with acquired feline infectious peritonitis receiving prolonged treatment with the 3CL-PR inhibitor GC376 (Pedersen et al., 2018; Perera et al., 2019) . Considering single (N25S, A252S or K260N), double (N25S+K260N) or triple (N25S+A252S+K260N) amino acid changes, only those containing N25S where associated with a marginal reduction in susceptibility to GC376 (Perera et al., 2019) . Conversely, drug resistance profiles to lopinavir, used in clinical practice for the treatment of SARS-CoV-2 infected patients have not yet been defined.

Overall, limited information is available on the emergence of drug resistance against RdRp and 3CL-PR inhibitors. While drug resistance against the above-mentioned active RNA polymerase inhibitors was difficult to select also due to the presence of ExoN, mutations conferring resistance to 3CL-PR inhibitors tend to emerge rapidly. However, for both drug-classes, the resistance phenotype impaired viral fitness in vitro and attenuated virulence in in vivo models. Identifying and understanding drug resistance against anti-coronavirus agents will be a crucial aspect that deserves to be finely elucidated for optimized antiviral strategies.

A comprehensive characterization of conserved regions in 3CL-PR, RdRp and spike from SARS-CoV-2, and other human coronaviruses, is of crucial importance for the best definition of targets for the design and development of novel compounds with anti-pan-coronavirus activity. This is critical since coronaviruses are endowed by high tendency to spillover from animals to humans, and thus future cross-species transmission events leading to severe outbreaks in humans are not unexpected.

Overall, this reinforces the need to set up an armamentarium of effective drugs to be used as treatment and/or prophylaxis to cope with potential future coronavirus infections. In particular, the identification of conserved regions, essential for viral replication and thus with no/very limited J o u r n a l P r e -p r o o f tendency to mutate, may offers the basis for the identification of pharmacological targets associated with a limited natural drug resistance and potential pan-activity versus all human coronaviruses.

The degree of conservation was defined on a large number of SARS-CoV-2 sequences retrieved from the start of the epidemic, from GISAID public database (https://www.gisaid.org/), with a total of 11,918 3CL-PR, 11,185 RdRp and 9,111 Spike glycoprotein sequences. The degree of conservation in SARS-CoV-2 was compared to that observed in sequences from SARS-CoV-1 (N=40), MERS-CoV (N=242) and other human coronaviruses (N=55 for HCoV-NL63, 21 for HCoV-229E, 15 for HCoV-HKU and 126 for HCoV-OC43).

The analysis of the 3CL-PR sequences from SARS-CoV-2 infected patients revealed a very high degree of genetic conservation. Indeed, 98.0% (300/306) amino acid residues showed < 0.1% variability (Table 3) . Among them, 179 residues were found never mutated. Even more, in the remaining 6 residues, the degree of variability never exceeds 5%. The analysis of specific domains revealed that, the highest degree of genetic conservation was observed in domains II and III with 100% and 100% of residues showing ≤ 0.1% variability. A slight decrease in the extent of genetic conservation was found for domain I with 96.7% of residues with ≤ 0.1% variability.

A high degree of genetic conservation was also observed for other species of human coronaviruses with a percentage of conserved residues ranging from 93.4% for HCoV-OC43 up to 99.0% for HCoV-NL63. Overall findings support a limited 3CL-PR genetic diversification within each species of human coronaviruses (Table 3) .

A completely different scenario is observed when 3CL-PR sequences from all human coronaviruses were compared (Table 4) . Here, only 85 residues were found conserved across the different species of human coronaviruses. In particular, these invariant residues were scattered throughout the individual sequence or forming conserved regions composed of at most 5 residues ( Figure 1 ). Expectedly, the two residues involved in the catalytic dyad were fully conserved: The His residue at position 41 resides in the largest conserved region encompassing amino acids 38-42, whereas the Cys residue at position 145 is located within a conserved triplet encompassing positions 145-147 ( Figure 1 ). Beyond the catalytic dyad, other 15 residues comprise the substrate-binding cleft as evident from the crystal structure of SARS-CoV-1/2 3CL-PR (Hsu et al., 2005; Muramatsu et al., 2016; Goyal and Goyal, 2020; Zhang, Lin, Sun, et al., 2020) Among them, only 5 residues (at positions 147, 163, 166, 187 and 192) were fully conserved (Zhang, Lin, Sun, et al., 2020) , while the remaining tend to have a group-specific pattern of amino acids. Particular attention should be given to the Ser residues at positions 139 and 147 located near the active site. Indeed, mutations at these positions can profoundly abrogate protease activity J o u r n a l P r e -p r o o f suggesting that targeting this site can serve as the basis for broad-spectrum therapeutic agents against 3CL-PR (Bacha et al., 2004; Barrila et al., 2010; Goyal and Goyal, 2020) .

CoV-2 3CL-PR (Zhang, Lin, Kusov, et al., 2020; Zhang, Lin, Sun, et al., 2020) . These compounds can interact with residues at positions 1, 40, and 166 in the core of the substrate-binding cleft (Zhang, Lin, Sun, et al., 2020) . The high degree of conservation across all human coronaviruses of the residues involved in the substrate binding cleft supports a potential anti pan-coronavirus activity of these compounds that deserves further investigation.

Among the 10 residues involved in the dimerization (Goyal and Goyal, 2020; Zhang, Lin, Sun, et al., 2020) , 6 residues at positions 14, 28, 139, 140, 290 and 299, were conserved across the different species. The remaining residues at positions 4, 10, 11, 298, were characterized by a groupspecific pattern of genetic diversification ( Figure 1 ).

The analysis of the RdRp sequences from SARS-CoV-2 isolated from infected patients revealed a very high degree of genetic conservation. Strikingly, 98.8% of the amino acid residues (560/567) displayed < 0.1% variability (Table 3) . Among them, 420 residues were found to be never mutated and the remaining 7 residues displayed a very low degree of variability never exceeding 1%. As evident form the analysis of specific domains, the thumb domain showed the highest degree of genetic conservation with 100% of residues exhibiting ≤ 0.1% variability (105/105), whereas the finger and palm domains exhibited 98.2% (270/275) and 98.9% (173/175) amino acid conservation, respectively.

As observed for 3CL-PR too, the other species of human coronaviruses showed a high degree of genetic conservation in RdRp with a residues conservation ranging from 95.9% for HCoV-NL63 up to 99.8% for MERS-CoV, re-indicating a limited intra-species genetic variability (Table 3) .

However, unlike 3CL-PR, a higher degree of RdRp genetic conservation across all human coronaviruses was observed with nearly 50% of the amino acid residues fully conserved (271/567) (Table 4, Figure 2 ). This corroborates the crucial role of this enzyme for viral replication and life cycle and its role as a druggable target for a pan-coronavirus pharmacological approach. In particular, a large fraction (45.4%) of conserved residues (123/27) clustered into 21 regions composed of 4 to 12 consecutive invariant residues, while the remaining invariant residues were scattered throughout the sequence, either individually or either pairs or triplets ( Figure 2 ).

In motif A (encompassing aa 611-627), 14 out of 17 residues were conserved including the classic divalent cation-binding residue Asp618 ( Figure 2 ). The RdRp Asp618 is known to be J o u r n a l P r e -p r o o f conserved in most viral polymerases including that of hepatitis C virus (corresponding to Asp220) and of poliovirus (corresponding to residue Asp233) (Gong and Peersen, 2010; Appleby et al., 2015) .

A superimposable scenario is observed for motif C (aa:753-767) with 13/15 residues fully conserved including the catalytic residues Ser759, Asp760 and Asp761 crucial for RNA-dependent RNA synthesis (Subissi et al., 2014; Gordon et al., 2020) . Notably, in motif C, the variant residue at position 766 was a Tyr in all species with the exception of SARS-CoV-2 in which a Phe was observed ( Figure 2 ). Further studies are necessary to determine whether the presence of a Phe can confer higher processivity to SARS-CoV-2 RdRp. Similarly, the variant residue at position 762 was a Gly in all species with the exception of the group 2b coronaviruses including SARS-CoV-1 and SARS-CoV-2 in which an Ala was present, suggesting a group-specific genetic adaptation (Figure 2 ).

The positively charged residues at position 545, 553 and 555, located in motif F and involved nucleotide triphosphate (NTP) entry channel are also fully conserved across the different species of human coronaviruses, as well as residues Asp623, Asn691 and Ser682 capable of recognizing the 2'-OH group of the NTP, thus allowing the RdRp to be specific for the synthesis of RNA rather than DNA ( Figure 2 ) (Hillen et al., 2020) .

Recently, residues involved in the interaction with remdesivir have been characterized (Gao et al., 2020; Hillen et al., 2020) . In particular, it has been shown that residue Thr680 forms hydrogen bonds not only with the incoming endogenous NTP but also with the 2′ OH of remdesivir, while residue Val557 stabilizes the interaction with the incoming triphosphate remdesivir (Gao et al., 2020) .

Other residues (Arg555, Ser682, Asp623 and Asn691) are located close to the region involved in remdesivir interaction and Asn691 is also potentially involved in the interaction with sofosbuvir (Gao et al., 2020) . All of them are were fully conserved across human coronaviruses ( Figure 2 ).

The analysis of the spike glycoprotein sequences too, within each species, showed a high degree of genetic conservation despite being a surface glycoprotein. Overall, in SARS-CoV-2, 98.5% of the amino acid residues (1254/1273) showed < 0.1% variability with no difference between the S1 and S2 subunits (98.4% [674/685] in subunit S1 and 98.6% [580/588] in subunit S2) (Table 3) .

Among them, 897 residues were never found mutated (476 in S1 and 421 in S2). Notably, only the Asp residue at position 614, mapping in the junction between subunit S1 and S2, showed a high degree of genetic variability exceeding 60%. The main mutation observed at this residue was D614G which has been proposed as a novel serine protease cleavage site capable of significantly enhancing the fusion with cell membrane in vitro (Bhattacharyya et al., 2020) .

By analyzing specific domains, the highest degree of genetic conservation was observed in the receptor binding domain (99.1% of residues with ≤ 0.1% variability), fusion peptide (100%), J o u r n a l P r e -p r o o f Heptad repeat region 2 (100%), and in the transmembrane domain (100%). A slight reduction in the extent of genetic conservation was found for the heptad repeat region 1 and for the cytoplasmic domain with 97.4% and 97.2% of residues with ≤ 0.1% variability, respectively.

High degree of genetic conservation was also observed for other species of human coronaviruses ranging from 85.9% in HCoV-OC43 up to 98.1% in SARS-CoV-1 for subunit 1, and from 96.0% in HCoV-OC43 up to 99.7% in HCoV-HKU1 for subunit 2. The higher degree of conservation in subunit S2 than in S1 can be explained by the fact that the S1 subunit is exposed to the environment and can thus be subject to immunological pressure (Table 3 , Figures 3 and 5C ).

The inter-species analysis of the spike subunits compared to SARS-CoV-2, confirmed the higher degree of conservation in subunit S2 than in S1 across human coronaviruses, ranging from 15.3% in HCoV-229E up to 63.9% in SARS-CoV-1 for subunit 1, and from 32.8% in HCoV-NL63 up to 90.0% in SARS-CoV-1 for subunit 2 (Table 4 ). In particular, the inter-species analysis of subunit S2 revealed that 109/240 residues were conserved across human coronaviruses ( Figure 3 ).

Most of them (70/109) were found to be clustered in regions composed of at most 4 residues, while the remaining 39 residues were scattered individually throughout the S2 subunit.

The heptad repeat 1 was the most conserved domain with 32.8% (24/73) of invariant residues.

In group 1b (HCoV-NL63 and HCoV-229E), this region (encompassing positions 939-940) was characterized by a long insertion of 14 residues, mainly identical (10/14). In the heptad repeat 1, between residues 922-943, we found 9 specific amino acids in SARS-CoV-2 which were different from SARS-CoV-1; furthermore, three amino acids were also different from all other human coronaviruses ( Figure 3 ). This is in line with a recent study suggesting that these unilateral replacements in the heptad repeat domain 1 of SARS-CoV-2 could enhance the interactions between heptad repeat 1 and 2, thus further stabilizing the 6-helices bundle and in turn increasing viral infectivity (Xia, Liu, et al., 2020) . In particular, this study showed that the presence of a Ser residue at position 929 can determine the establishment of a novel hydrogen bond (not observed in SARS-CoV-1) with the Asn at position 1192 (Xia, Liu, et al., 2020) . In line with a higher degree of conservation, the heptad repeats 1 has been proposed as a target for the development of viral fusion inhibitors with group-specific (Lu et al., 2014; Channappanavar et al., 2015) or with anti-pancoronavirus activity (Xia, Liu, et al., 2020; Xia, Zhu, et al., 2020) . Among them, the compound EK1C4 showed a broad-spectrum inhibitory activity against infection by SARS-CoV-2, SARS-CoV-1, MERS-CoV and other HCoVs. Furthermore, EK1C4 was characterized by long-lasting prophylactic effect against HCoV-OC43 in mice, supporting its use against SARS-CoV-2 infection (Xia, Liu, et al., 2020) .

The other domains of subunit 2 showed a degree of conservation ranging from 7.8% for the heptad repeat 2 up to 16% for the transmembrane domain, while no conserved residues were detected in the fusion peptide.

Completely different scenario is observed for subunit S1 which displays remarkable tendency towards group-specific amino acids profile (Figure 4 ). For this reason, the analysis of genetic conservation was carried out by comparing subunit S1 sequences within each group of human coronaviruses separately, and was focused on the receptor binding domain (RBD), the key functional component of subunit S1.

In group 2b (comprising SARS-CoV-1 and SARS-CoV-2, both of which use the ACE2 receptor for their entry), 73.5% (164/223) showed a full genetic concordance (Figure 4) . These include the 8 Cys residues at positions 336, 361, 379, 432, 391, 480, 488 and 525, crucial for the establishment of disulfide bonds that stabilize the RBD structure (Lan et al., 2020) . A recent study has identified 14 SARS-CoV-2 residues involved in the interaction with the ACE2 receptor (Lan et al., 2020) . Among them, only 8 were shared and conserved among both SARS-CoVs: Tyr449, Tyr453, Asn487, Tyr489, Gly496, Thr500, Gly502 and Tyr505 of SARS-CoV-2 (corresponding to Tyr436, Tyr440, Asn473, Tyr475, Gly482, Thr486, Gly488 and Tyr491 in SARS-CoV-1, respectively) (Lan et al., 2020) . Among them, Tyr residues at positions 449, 489 and 505 in SARS-CoV-2 were critical for the establishment of hydrogen bonds with polar hydroxyl groups in ACE2.

Conversely, 5 positions were characterized by different amino acids with superimposable biochemical properties: Leu455/Tyr442, Phe456/Leu443, Phe486/Leu472, Gln493/Asn479 and Asn501/Thr487 (corresponding to the respective Tyr442, Leu443, Leu472, Asn479 and Thr487 in SARS-CoV-1) (Lan et al., 2020) . The remaining positions corresponds to Gln498 and Tyr484 in SARS-CoV-2 and SARS-CoV-1 (Lan et al., 2020) .

Previous studies have shown that SARS-CoV-2 RBD is endowed with significantly higher binding affinity to ACE2 than SARS-CoV-1. Thus, it is conceivable to hypothesize that the amino acids changes have been evolved in order to optimize such interaction. Interestingly, this finding can be explained by the fact that, while HCoV-NL63 interacts with ACE2, HCoV-229E specifically binds to the aminopeptidase N (APN or CD13). Thus, the different receptor usage can pose a different selective pressure favoring a substantial degree of genetic diversification.

With the aim to represent the 3D localization of all the conserved regions, we report the surface optimized structures of SARS-CoV-2 3CL-PR ( Figure 5A ), RdRp ( Figure 5B ) and spike S2 subunit ( Figure 5C ) by coloring the residues that are conserved in all coronaviruses, those conserved in SARS-CoV-2, SARS-CoV-1 and MERS-CoV, those conserved in SARS-CoV-2 and SARS-CoV-1, those conserved in SARS-CoV-2 and at least another coronavirus, as well as those that are present solely in SARS-CoV-2 respectively, in blue, light blue, pale cyan, salmon and red. Interestingly, we could observe some highly conserved putative additional binding pockets in both 3CL-PR and RdRp that will be further investigated in future studies.

The glycosylation of proteins present in the viral envelope, plays a critical role in viral pathogenesis The high degree of conservation of the N-linked glycosylation sites, particularly in highly pathogenic coronaviruses, suggests their role as a target of the so-called carbohydrate-binding agents (CBA), an intriguing class of antiviral compounds capable to prevent viral entry into the target cell. Interestingly, previous studies have shown that long-term pharmacological pressure with CBA can result in the selection of resistant viral strains with mutations abrogating the N-linked glycans (François and Balzarini, 2012) . Since the shield of carbohydrates can mask viral epitopes from neutralizing antibodies, CBAs could also enhance the capability of the immune system in blocking viral infection J o u r n a l P r e -p r o o f (François and Balzarini, 2012) . A previous study has shown that CBA can efficiently inhibit SARS-CoV-1 replication (Keyaerts et al., 2007) , supporting their role, not only for treatment but also for prevention of coronavirus infection.

Potential new antiviral agents against SARS-CoV-2 and other human pathogenic coronaviruses based on structural modeling.

As previously discussed, albeit their high species diversity, coronaviruses share key genomic elements that are crucial for drug design process. Two viral proteases, the papain-like protease (PLpro) and the 3CL-PR, are involved in cleaving the large replicase polyprotein 1a (pp1a) and pp1ab

to produce NSPs, such as RdRp and helicase, responsible for the replication and transcription of the virus (Boheemen et al., 2012; . The surface structural spike glycoprotein, composed of the amino-terminal receptor-binding S1 and carboxy-terminal membrane fusion S2 subunits, is of particular interest for antiviral development because of its critical role in the virus-host cell receptor interaction. Binding of the S1 subunit RBD to the host receptor triggers conformational changes in the S2 subunit (the stalk region of S) to enable fusion (Lu et al., 2014) . ACE2 (used by SARS-CoV-1 and -2 as well as HCoV-NL63), dipeptidyl peptidase 4 (DPP4; used by MERS-CoV), aminopeptidase N (used by HCoV-229E), and O-acetylated sialic acid (used by HCoV-OC43 and HCoV-HKU1) represent the key functional host cell receptors utilized by human pathogenic coronaviruses (Vlasak et al., 1988; Yeager et al., 1992; Li et al., 2003; Hofmann et al., 2005; Raj et al., 2013; Huang et al., 2015) . In order to promote the process of cell surface non-endosomal virus entry at the plasma membrane, other host proteases, such as transmembrane protease serine 2 (TMPRSS2) and TMPRSS11D (also known as airway trypsin-like protease), cleave the spike into the S1 and S2 subunits (Shirato, Kawase and Matsuyama, 2013) . The MERS-CoV spike is also activated by furin, a serine endoprotease implicated in the processing of fusion proteins and cell entry of other RNA viruses. Furin is also involved in MERS-CoV S1/S2 cleavage during egress from the infected cell (Mille and Whittaker, 2014) .

Before the SARS epidemic, only two human pathogenic coronaviruses (HCoV-229E and HCoV-OC43 were known, as usually associated with self-limited upper respiratory tract infections (Chan et al., 2012) . Therefore, when the high pathogenic SARS-CoV-1 suddenly emerged in the late

The first approach to drug discovery was based on testing existing broad-spectrum antiviral drugs that have been used to treat other viral infections by using standard assays that measure the effects of these drugs on the cytopathic effect, virus yield and plaque formation of live and/or pseudotyped coronaviruses. Examples of drugs identified using this approach include interferon α, interferon β, interferon ɤ, ribavirin and inhibitors of cyclophilin (Cinatl et al., 2003; So et al., 2003; Pfefferle et al., 2011; Chan et al., 2013; de Wilde et al., 2013; Falzarano, De Wit, Martellaro, et al., 2013; Tanaka, Sato and Sasaki, 2013) . The advantage of using these drugs is related to their availability with known pharmacokinetic and pharmacodynamic properties, side effects and dosing regimens. However, they do not have specific anti-coronaviruses effects and may be associated with severe adverse effects.

The second anti-coronavirus drug discovery approach was represented by a drug repurposing screening method that involves chemical libraries comprising large numbers of existing compounds or databases Elshabrawy et al., 2014) . This approach allows to rapidly identify many readily available compounds that can then be further characterized by antiviral assays. Albeit many of the identified drugs exhibit anti-coronavirus activities in vitro, most are not clinically useful because they are either associated with immunosuppressive effects or have therapeutic dosage limitations.

The third approach for anti-coronavirus drug discovery was based on the de novo development of novel, specific agents thanks to the genomic and biophysical understanding of the individual coronaviruses, such as siRNA molecules or inhibitors that target specific viral enzymes involved in the viral replication cycle. Although most of these drugs have potent in vitro and/or in vivo anticoronavirus activity, their pharmacokinetic and pharmacodynamics properties and side effect profiles have yet to be evaluated in animal and human trials. Furthermore, the development of these candidate drugs into clinically useful therapeutic options with reliable delivery modes for patients usually takes years (Zumla et al., 2016) . In this perspective, in the drug development process, several computational methods, and in particular virtual screening (VS) techniques, proved to be important tools to speed up the process. During the early 1980s, the ability to rationally design drugs using protein structures was an unrealistic goal for many structural biologists. The first projects were underway in the mid-80s, and by the early 1990s the first success stories were published (Erickson et al., 1990; Roberts et al., 1990; Dorsey et al., 1994) . Today, even though there is still quite a bit of fine-tuning necessary to perfect the process, structure-based drug design is an integral part of most industrial drug discovery programs (Mountain, 2003) and is the major subject of research for many academic research laboratories. The improvement of both proteomics and structural genomics and the development in information technology played a key role for the success story in the discovery J o u r n a l P r e -p r o o f of new lead drugs. Excellent drug targets are identified at an increasing pace using developments in bioinformatics. High-throughput crystallography, as well as nuclear magnetic resonance (NMR), have seen a number of advances in the past years, thus shortening the timeline for determining structures. Faster computers and the availability of relatively inexpensive clusters of computers have increased the speed at which drug leads can be identified and evaluated in silico.

By exploiting these increasingly advanced technologies, it has been possible to design very promising molecules able to recognize different targets of the β-coronaviruses.

Specifically, the SARS-CoV-1 main protease has been comprehensively explored as a drug target, and many potent enzyme inhibitors have been identified (Bacha et al., 2004; Grum-Tokars et al., 2008) . Interestingly, as discussed above, 3CL-PR enzymes from different coronaviruses are known to share significant sequence and 3D structural homology providing a strong structural basis for designing wide-spectrum anti-coronavirus inhibitors ( Figure 5A ) (Yang, Bartlam and Rao, 2006; Wang et al., 2016) 

Structure-Activity Relationship (QSAR)-guided modeling together with docking simulations in order to carry out the first pharmacophore modeling study of a set of peptidomimetic inhibitors of the bat HKU4-CoV 3CL-PR. Specifically, the structural features pivotal in ligand recognition, as well as the most important 3CL-PR binding pocket regions, were highlighted by the obtained pharmacophore models, that were further used to screen the National Cancer Institute database for novel non-peptidomimetic 3CL-PR inhibitors. The identified hits were tested as potential HKU4-CoV and MERS-CoV 3CL-PR inhibitors. Among them, two phenylsulfonamide derivatives displayed moderate inhibitory activity against the MERS-CoV 3CL-PR, thus representing a potential starting point for the development of novel anti-MERS agents (Abuhammad et al., 2017) .

The same target of the six human coronaviruses HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV-1 and MERS-CoV was also investigated by Berry and coworkers, who screened the ZINC drugs-now library by applying both high-throughput pharmacophore modeling and molecular docking experiments. The results obtained from the consensus virtual screening approach, performed by using Vina, Glide, GOLD and MM-GBSA, were further validated by means of molecular dynamics simulations. The authors identified 19 best hits and characterized them in terms of shape and features, thus highlighting 15 significantly dissimilar clusters. Interestingly, in the perspective of a future lead optimization, the incorporation of a lactam ring was strongly suggested since it was found to enhance the interactions of the natural substrate and is also effective against the SARS-CoV-1 3CL-PR (Berry, Fielding and Gamieldien, 2015).

represented by the ACE2 receptor, considered an important therapeutic target for controlling J o u r n a l P r e -p r o o f cardiovascular diseases and SARS outbreaks. Specifically, in a study published in 2004, about 140000 small molecules were screened by in silico molecular docking, and those with the best in silico binding affinity were tested for their ability to inhibit both ACE2 catalytic activity and SARS-CoV-1 spike protein-mediated cell fusion. The N-(2-aminoethyl)-1-aziridine-ethanamine was identified as a novel ACE2 inhibitor that is also effective in blocking the SARS-CoV-1 spike proteinmediated cell fusion (Huentelman et al., 2004) .

More recently, by applying in silico docking models, a library of known bioactive compounds against several sites on the spike protein and the catalytic site of the SARS-CoV-2 3CL-PR has been screened. Many ligands were identified as promising inhibitors for SARS-CoV-2, such as zanamivir, indinavir, saquinavir and remdesivir, able to well recognize the viral main protease (Hall and Ji, 2020) .

In a drug repurposing perspective, the SARS-CoV-2 RdRp was modeled and targeted using different anti-polymerase drugs already approved against various viruses, such as HIV, HCV and Ebola. The authors showed the potential effectiveness of ribavirin, remdesivir, sofosbuvir, galidesivir and tenofovir as potent inhibitors of SARS-CoV-2 RdRp, and also suggested a guanosine derivative (IDX-184), setrobuvir and YAK as the most promising antiviral leads to specifically combat the SARS-CoV-2 strain (Elfiky, 2020) . Recently, by structurally superposing the HCV polymerase bound to sofosbuvir with the SARS-CoV RdRp, Jácome and coworkers demonstrated that the residues of the drug-binding pocket are present also in RdRp. Moreover, these residues were found to be conserved in several SARS and MERS-related coronaviruses polymerases, thus suggesting the possibility to use sofosbuvir against these highly infectious pathogens (Jácome et al., 2020) .

Another in silico drug repurposing study was carried out against the main protease of SARS-CoV-2. The authors combined docking experiments with molecular dynamics simulations (MDs) in order to screen 1,615 FDA-approved against the enzyme active site. Specifically, the predicted binding modes of the top scoring hits were fully characterized by MDs and, in agreement with other recent in silico drug repurposing studies, aliskiren, capreomycin and isovuconazonium, as well as ceftolozane, cobicistat and carfilzomib emerged as novel potential inhibitors (Qiang Wang et al., 2020) . Saquinavir was also well ranked, but MDs revealed an unstable binding mode. In addition, the protocol favorably ranked dronedarone, a molecule recently reported as an active inhibitor of SARS-CoV-2 virus (Jeon et al., 2020) , suggesting that its target could be the viral main protease (Cesar and Alejandro, 2020) . This enzyme was also investigated by Abhithaj J. and coworkers, who applied pharmacophore modeling followed by docking simulations, by screening the DrugBank database and thus identifying cobicistat, larotrectinib and simeprevir as potential candidates for repurposing J o u r n a l P r e -p r o o f (Abhithaj et al., 2020) . Other very promising compounds selected by means of another recent structure-based VS were two directly-acting antiviral drugs, that are velpatasvir and ledipasvir, both of which are inhibitors of the HCV NS5A protein and marketed as approved drugs in combination with sofosbuvir (Chen, Yiu and Wong, 2020) . Whereas, by means of a blind molecular docking approach against the SARS-CoV-2 3CL-PR, Das and collaborators identified 33 molecules, which included natural products, anti-virals, anti-fungals, anti-nematodes and anti-protozoals, able to well recognize the viral enzyme, with rutin showing the highest inhibitor efficacy (Das et al., 2020) . All published repurposed drugs identified by computational techniques are depicted in Table S1 .

In this context, our research group also applied an in silico drug repurposing approach by investigating the molecular recognition of the DrugBank database, thus including about 15,000 small molecules (approved drugs, experimental and investigational compounds, as well as nutraceuticals) against: a) the crystal structure of the complex resulting from the interaction between SARS-CoV-2 main protease and tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-((S)-2-oxopyrrolidin-3yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate (alpha-ketoamide 13b) (PDB code 6Y2G); b) the structure of the chimeric receptor-binding domain of spike of SARS-CoV-2 complexed with its receptor human ACE2 (PDB code 6VW1), considering both ACE2 alone and in complex with spike, as well as c) the nsp12-nsp7-nsp8 complex bound to the template-primer RNA and triphosphate form of remdesivir (PDB code 7BV2). All the experimental details are reported in the Supporting Information.

Based on their theoretical binding affinity, expressed as Glide-score (G-score), we filtered the best molecules obtained by our structure-based VS, selecting only those with a score within 2 kcal/mol above the minimum energy. Thereby, we selected ~100 compounds for each analyzed target, and by visual inspection and chemical diversity, we identified the most promising ones characterized by a good theoretical binding affinity towards at least two of the four studied targets. Specifically, as reported in Table 5 , we found 4 cephalosporins, 2 flavone compounds, 3 purine analogues (including remdesivir), 2 peptide derivatives, 2 triazoles and a benzeneacetamide, identified as the best 14 candidates that deserve further investigation in future in vitro studies to test their potential antiviral activity.

As shown in the Supporting Information (Figures S1-S5) , most of the identified compounds were involved in several hydrogen bonds (HBs) with some crucial residues of the viral main protease, such as Asn142, Gly143, Cys145, Glu166 and Thr190, as well as in many Van der Waals contacts and a pivotal π-π stacking interaction with His41 (the residue involved in the catalytic dyad together J o u r n a l P r e -p r o o f with Cys145). The other four 3CL-PR residues are part of the substrate-binding cleft and are fully conserved among SARS-CoVs (Figure 1 ).

Regarding the RdRp, Lys545, Ser549, Lys551 and Arg553 were found to establish a strong hydrogen bonding network with most of the selected molecules, further stabilized by means of additional HBs with some RNA nucleobases, such as uracil at position 18, adenine at position 19 and uracil at position 20, also involved in salt bridges and π-cation interactions (Supporting Information, Figures S6-S10) . All 4 residues are located in the RdRp Motif F and are fully conserved among all human coronaviruses (Figure 2) . We observed that all the studied cephalosporins were able to interact with the magnesium cations, both by means of coordination and π-cation interactions, thus rationalizing their better theoretical affinities towards the viral enzyme.

In the molecular recognition of the ACE2 host protein, many residues of the catalytic domain were involved in productive interactions with several analyzed drugs, such as Asp206, Asn394, Arg514 and Lys562, able to establish HBs together with salt bridges and π-cation interactions (Supporting Information, Figures S11-S15). Moreover, argifin and three of the four cephalosporins were able to coordinate the divalent zinc cation present in the catalytic site, thus increasing their stabilization within the enzyme binding pocket.

Finally, by analyzing the ACE2-spike interface region, we observed that most of the identified compounds were involved in HBs with Glu35, Asp38, Lys68 and Glu75 residues of ACE2 enzyme.

Moreover, Lys31 and Lys68 were found to establish crucial salt bridges and π-cation interactions with several ligands, as reported in the Supporting Information (Figures S16-S20 ).

Among the most promising drugs, ceftolozane, a semi-synthetic broad-spectrum fifth generation cephalosporin approved by the FDA for use in combination with tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and the coenzyme NADH, useful in treating Parkinson's disease, chronic fatigue syndrome, Alzheimer's disease and cardiovascular pathologies, were able to well recognize all the investigated targets, thus providing the best potential multi-targeting profile.

As shown in Figure 6A , ceftolozane was involved in 7 HBs and a salt bridge within the 3CL-PR binding pocket, while in the RdRp best pose, the cephalosporin was well stabilized through several interactions among its heterocyclic rings and both RNA nucleobases and lysine residues at positions 545 and 551 ( Figure 6B ). Within the ACE2 catalytic site, as well as at the interface with the spike glycoprotein, the anti-bacterial antibiotic was involved in 4 HBs and a salt bridge ( Figure 6D and 6C).

The interesting results related to ceftolozane and to the other identified cephalosporins could rationalize the suggestion of Berry and coworkers (Berry, Fielding and Gamieldien, 2015) to incorporate a lactam ring in the lead optimization process of potential SARS-CoV 3CL-PR inhibitors.

As evident from Figure 7A , NADH was well stabilized within 3CL-PR binding pocket by means of 8 HBs, while after the molecular recognition of the viral RdRp, the coenzyme was involved in 3 HBs, 2 salt bridges and one π-cation interaction ( Figure 7B ). Within the ACE2 catalytic site and at the interface with the spike glycoprotein, NADH was found to establish, respectively, 8 and 6 HBs and a salt bridge ( Figure 7D and 7C).

Our results, which are in accord with some published data, suggest a potential multi-targeting behavior of the screened compounds, thus potentially reducing the generation of drug resistant viral strains. We are interested in seeing these compounds move to drug testing as antivirals against SARS-CoV-2, and in vitro studies are underway in our laboratory in this respect.

The urgent identification of effective interventions against SARS-CoV-2 infection is a major challenge. The development of new effective broad-spectrum drugs targeting coronaviruses will increase the number of therapeutic options for patients with SARS-CoV-2 and other pathogenic coronaviruses infection. In this review the current antiviral strategies and global efforts towards the development of novel compounds aimed at coping with the infection sustained by SARS-CoV-2 and other pathogenic human coronaviruses have been discussed, with a particular focus on antiviral drugs already tested in clinical trials and able to inhibit viral protease, polymerase and spike glycoprotein. With the overall increased numbers of treated patients with new antivirals, it will be important to increase our understanding of efficacy, safety in the context of the COVID 2019 disease, and the molecular mechanisms by which this virus acquires drug resistance. This review also provided insight on the peculiar coronavirus mechanisms underlying resistance, highlighting a sort of innate drug resistance to RdRp nucleoside analogues, mediated by the exonuclease genomic proofreading mechanism. Conversely, paucity of information is available on the profiles of drug resistance mutations against anti-coronavirus agents, so filling this gap is crucial in optimizing antiviral strategies.

Moreover, a large dataset of coronaviruses genomic sequences has been evaluated, thus providing a comprehensive map of conserved regions in the abovementioned viral proteins across human coronaviruses. In particular, the analysis of 3CL-PR, RdRp and spike glycoprotein sequences from SARS-CoV-2 infected patients revealed a very high degree of genetic conservation, with 98.0%, 98.8% and 98.5% amino acid residues showing < 0.1% variability, respectively. Interestingly, these highly conserved protein regions could represent novel pharmacological targets for compounds with antiSARS-CoV-2 activity to be thoroughly investigated in future studies. Furthermore, by applying an in silico drug repurposing approach, we analyzed the molecular recognition of the DrugBank database against the viral protease, polymerase and the human ACE2 enzyme, alone and in complex with the receptor-binding domain of the spike glycoprotein, thus identifying the most promising compounds displaying a good theoretical binding affinity towards at least two of the four studied targets. In particular, we identified 4 cephalosporins, 2 flavone compounds, 3 purine analogues (including remdesivir), 2 peptide derivatives, 2 triazoles and a benzeneacetamide. Most of the identified compounds were well recognized by the target receptors through several productive interactions with crucial residues of both viral and host proteins, thus increasing their in silico binding affinity. Among which, the 5 th generation antibacterial cephalosporin ceftolozane and the coenzyme NADH exhibited the best multi-targeting profile. Interestingly, we observed that all the studied cephalosporins were well ranked against all the targets studied, thus confirming the key role of the βlactam ring in the drug discovery process as already proposed for SARS-CoV-1 inhibitors. Therefore, a very promising future direction in the research of novel anti-coronavirus agents could be represented by the lead optimization of such a chemical scaffold. Further in vitro studies are necessary in order to verify the antiviral activity of the top rating molecules against SARS-CoV-2 and hopefully their ability to alleviate the emergence as well as surmount drug resistant viral strains.

As abovementioned, the current review provides not just classical evidence, but also highlights innovative antiviral drugs. Other future directions could be developed to also antagonize other nonstructural and structural viral proteins, or modulate essential host elements of viral infection. For instance, other potential targets could be based on the design of drugs targeting cell machinery, such as the stimulation of the autophagy process. Indeed, it is known that SARS-CoV-2 (like other human coronaviruses) can hamper the unfolded protein response (UPR) and consequently the induction of autophagy in order to improve its replicative capacity. In this perspective, a very intriguing therapeutic strategy could be to unlock the virus induced autophagy blockage, thus decreasing viral replication capacity (Boga and Coto-Montes, 2020) .

Overall, this review corroborates the urgent need to define highly effective and innovative broadspectrum antiviral agents aimed at coping the current and the future unavoidable outbreaks of coronaviruses. Warren, T. K. et al. (2016) Goyal et al., 2020; , while residues composing the substrate-binding cleft are in dark blue according to Muramatsu et al.,2016; Hsu et al., 2005; Goyal et al., 2020 . The domains of 3CL-PR are reported according to . Conserved amino acids across human coronaviruses are indicated by dots and highlighted in cyan.

Residues encompassing motifs A-E are highlighted in light blue. The catalytic residues S759, D760

and D761 and the classic divalent-cation-binding residue D618 are highlighted in dark red.

The start and end of each RdRp functional domains (fingers, palm and thumb) are also indicated. The numbering of RdRp domains and motifs is according to Gao et al., Science 2020 J o u r n a l P r e -p r o o f Table 3 . Extent of genetic conservation in 3CL-Protease, RNA-dependent RNA polymerase and in the spike protein in the different human coronaviruses Table 4 . Degree of amino acid identity in 3CL-Protease, RNA-dependent RNA polymerase and in the spike protein across the different human coronaviruses compared to SARS-CoV-2 a Number of sequences analyzed are: 11,918 for SARS-CoV-2 3CL-PR, 11,185 for SARS-CoV-2 RdRp, and 9,111 for SARS-CoV-2 Spike), 40 for SARS-CoV-1 3CL-PR, RdRP and Spike, 126 for HCoV-OC43 3CL-PR, RdRP and Spike, 55 for HCoV-NL63 3CL-PR, RdRP and Spike, 20 for HCoV-229E 3CL-PR, RdRP and Spike, 15 for HCoV-HKU1 3CL-PR, RdRP and Spike, and 242 for MERS-CoV 3CL-PR, RdRP and Spike. The degree of identity is calculated as the % of identical amino acid residues in a specific protein between SARS-CoV-2 and each of the other human coronaviruses. The denominator used to calculate the % is the number of residues in SARS-CoV-2 proteins: 306 for 3CL-PR, 567 for RdRp, 685 for the spike subunit 1 and 588 for the spike subunit 2. Abbreviations: 3CL-PR, 3CL protease; RdRp, RNA-dependent RNA polymerase 

Repurposing Simeprevir, Calpain Inhibitor IV and a Cathepsin F Inhibitor Against SARS-CoV-2: A Study Using in Silico Pharmacophore Modeling and Docking Methods', chemRxiv

Computational modeling of the bat HKU4 coronavirus 3CL pro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus'

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Small-Molecule Antiviral ␤ -D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Structural basis for RNA replication by the hepatitis C virus polymerase

Identification of Novel Inhibitors of the SARS Coronavirus Main Protease 3CL pro †

Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy

Teicoplanin: an alternative drug for the treatment of COVID-19?

Global Spread of SARS-CoV-2 Subtype with Spike Protein Mutation D614G is Shaped by Human Genomic Variations that Regulate Expression

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Environmental Contamination and Viral Shedding in MERS Patients During MERS-CoV Outbreak in South Korea

Arbidol as a broad-spectrum antiviral: An update

Deployment of convalescent plasma for the prevention and treatment of COVID-19

ER stress and autophagy induced by SARS-CoV-2: The targets for melatonin treatment

Genomic Characterization of a Newly Discovered Coronavirus

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19

Identification of Potential Inhibitors of SARS-CoV-2

Main Protease via a Rapid In-Silico Drug Repurposing Approach

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Is the discovery of the novel human betacoronavirus

HCoV-EMC) the beginning of another SARS-like pandemic?

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection

3C-like protease (3CLpro) structure: Virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates', F1000Research

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Treatment of SARS with human interferons

Hydroxychloroquine for the Prevention of Covid-19 -Searching for

Origin and evolution of pathogenic coronaviruses

Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection

An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study

A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo

Coronaviruses Resistant to a 3C-Like Protease Inhibitor Are Attenuated for Replication and Pathogenesis, Revealing a Low Genetic Barrier but High Fitness Cost of Resistance

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

L-735,524: The Design of a Potent and Orally Bioavailable HIV Protease Inhibitor

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy', Drug Resistance Updates

Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Identification of a Broad-Spectrum Antiviral Small Molecule against Severe Acute Respiratory Syndrome Coronavirus and Ebola, Hendra, and Nipah Viruses by Using a Novel High-Throughput Screening Assay

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

First COVID-19 treatment recommended for EU authorization

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

Potential of carbohydrate-binding agents as therapeutics against enveloped viruses

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Structural basis for active site closure by the poliovirus RNAdependent RNA polymerase

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Targeting the dimerization of main protease of coronaviruses: A potential broad-spectrum therapeutic strategy

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Evaluating the 3C-like protease activity of SARS-Coronavirus: Recommendations for standardized assays for drug discovery

Pathogenetic mechanisms of severe acute respiratory syndrome

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

New Flu Antiviral Candidate May Thwart Drug Resistance

Structure of replicating SARS-CoV-2 polymerase

Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry

First case of 2019 novel coronavirus in the United States

Mechanism of the Maturation Process of SARS-CoV 3CL Protease

3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base Mechanism †

Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19

Human Coronavirus HKU1 Spike Protein Uses O -Acetylated Sialic Acid as an Attachment Receptor Determinant and Employs Hemagglutinin-Esterase Protein as a Receptor-Destroying Enzyme

Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor

Ritonavir-boosted protease inhibitors in HIV therapy

Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic

Identification of antiviral drug candidates against SARS-CoV-2 from FDAapproved drugs

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2

Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle

Cell-based antiviral screening against coronaviruses: Developing virus-specific and broad-spectrum inhibitors

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Quasispecies theory and the behavior of RNA viruses

Coronavirus infections and immune responses

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)'

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor', Nature Communications

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding', The Lancet

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

RNA synthetic mechanisms employed by diverse families of RNA viruses

Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Astex, Structural Genomix, and Syrrx. I can see clearly now: structural biology and drug discovery

SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity

COVID-19) Treatment Guidelines. National Institutes of Health

Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)', Molecules

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Characterization of amino acid substitutions in feline coronavirus 3C-like protease from a cat with feline infectious peritonitis treated with a protease inhibitor

The SARS-Coronavirus-host interactome: Identification of cyclophilins as target for pan-Coronavirus inhibitors

Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review

Nucleoside analogues for the treatment of coronavirus infections', Current Opinion in Virology

Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses

Virtual screening of approved clinic drugs with main protease ( 3CL', Preprints

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC'

Rational design of peptide-based HIV proteinase inhibitors

A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping', Cells

Homology-Based Identification of a Mutation in the Coronavirus RNA-Dependent RNA Polymerase That Confers Resistance to Multiple Mutagens

A novel auto-cleavage assay for studying mutational effects on the active site of severe acute respiratory syndrome coronavirus 3C-like protease

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12

RdRp and nsp14 Exonuclease active-sites

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain

Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2

Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics', PLoS Pathogens

Development of a standard treatment protocol for severe acute respiratory syndrome

From SARS to MERS, thrusting coronaviruses into the spotlight

Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir

One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities

Suppression of coronavirus replication by cyclophilin inhibitors

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design', Scientific Reports

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Clinical Features of 69 Cases With Coronavirus Disease

Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture

Small molecules targeting severe acute respiratory syndrome human coronavirus

A new coronavirus associated with human respiratory disease in China

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Inhibition of SARS-CoV-2 (previously 2019membrane fusion

Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication

The structure and functions of coronavirus genomic 3′ and 5′ ends

Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Human aminopeptidase N is a receptor for human coronavirus 229E'

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors

α-Ketoamides as Broad-Spectrum Inhibitors of

Totura and Bavari

a Number of sequences analyzed are: 11,918 for SARS-CoV-2 3CL-PR, 11,185 for SARS-CoV-2 RdRp, and 9,111 for SARS-CoV-2 Spike, 40 for SARS-CoV-1 3CL-PR, RdRP and Spike, 126 for HCoV-OC43 3CL-PR, RdRP and Spike, 55 for HCoV-NL63 3CL-PR, RdRP and Spike, 20 for HCoV-229E 3CL-PR, RdRP and Spike, 15 for HCoV-HKU1 3CL-PR, RdRP and Spike, and 242 for MERS-CoV 3CL-PR, RdRP and Spike

conserved residues are defined as those in which aa substitutions are observed with a frequency <0.1%, while for all other coronaviruses, conserved residues were defined as those in which no aa substitutions were observed. Abbreviations: 3CL-PR

RNA-dependent RNA polymerase Coronavirus species % of conserved residues (N of conserved residues/Total N of residues in a protein

DrugBank code, drug name and Glide score (G-Score) values of the best 14 compounds identified by the structure-based virtual screening approach against the SARS-CoV-2 main protease (3CL-PR), polymerase (RdRp) and the host ACE2 enzyme, alone and complexed to the viral spike glycoprotein

This value indicates the absolute best G-score value for each analyzed target and is expressed in kcal/mol